Evidence map›Paper›PMID 29516417›Full record

ReviewMolecular biotechnology2018

Genome Editing in Stem Cells for Disease Therapeutics.

Minjung Song, Suresh Ramakrishna

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Minjung SongDepartment of Food Biotechnology, College of Medical and Life Science, Silla University, Busan, South Korea. songmj@silla.ac.kr.
Suresh RamakrishnaGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea. suri28@hanyang.ac.kr.ORCID http://orcid.org/0000-0002-4038-1085

Funding

National Research Foundation of Korea 2015R1C1A1A01054482National Research Foundation of Korea 2017R1D1A1A02018480
6 · The paper itself

Abstract

Programmable nucleases including zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindrome repeats (CRISPR)/CRISPR-associated protein have tremendous potential biological and therapeutic applications as novel genome editing tools. These nucleases enable precise modification of the gene of interest by disruption, insertion, or correction. The application of genome editing technology to pluripotent stem cells or hematopoietic stem cells has the potential to remarkably advance the contribution of this technology to life sciences. Specifically, disease models can be generated and effective therapeutics can be developed with great efficiency and speed. Here we review the characteristics and mechanisms of each programmable nuclease. In addition, we review the applications of these nucleases to stem cells for disease therapies and summarize key studies of interest.

Indexed as

CRISPR-Cas SystemsEndonucleasesGene EditingGenetic EngineeringHumansStem CellsStem Cell TransplantationTranscription Activator-Like Effector NucleasesEndonucleasesTranscription Activator-Like Effector NucleasesClustered regularly interspaced short palindrome repeat associated systemHematopoietic stem cellsInduced pluripotent stem cellsTranscription activator-like effector nucleasesZinc finger nucleases

Identifiers

PMID29516417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.